Rizatriptan Benzoate Tablet
Product Images NDC 82804-202

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 82804-202). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

82804-202-12 (E7414f2d D7cf 41e5 B457 F5850e8bb7a7 00)

This is a product label for Rizatriptan Benzoate tablets, each containing 10mg of the active ingredient. The tablets are pale pink in color, circular, flat, and beveled-edge, with "Riza" and "10mg" debossed on one side, and "14" on the other side. The tablets come in a package of 12 tablets. The medication is manufactured for Rising Health, LLC and made in India. The storage instructions recommend keeping the medication at 20°C-25°C (68°F-77°F). The label also includes lot numbers, expiration dates, and safety warnings to keep the medication out of reach of children.*

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

The text contains a chart showing the estimated probability of achieving an initial headache response within 2 hours after taking different doses of Rizatriptan Benzoate compared to a placebo. The data is based on pooled studies from placebo-controlled outpatient trials. The chart displays percentages at various time intervals post-dose, indicating the likelihood of headache response for each treatment group. This information can be useful for evaluating the effectiveness of Rizatriptan Benzoate in managing headaches.*

FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

This text provides information on the estimated probability of patients taking a second dose of Rizatriptan Benzoate tablets or other medication for migraines over the 24 hours following the initial dose of the study treatment in pooled Studies 1, 2, 3, and 4. The data is depicted in a Kaplan-Meier plot, which includes patients who had a headache response at 2 hours and those who did not. Remedication within 2 hours post-dose was not allowed and patients not using additional treatments were censored at 24 hours.*

FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig3)

This text provides information on the percent of patients reporting no headache pain after taking Rizatriptan Benzoate Orally Disintegrating Tablets compared to a placebo. The data is displayed at different time points up to 20 hours post-dose in a study context.*

FDA Label Image

Chemical Structure (Rizatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.